Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.65 |
| ▸ | FYN | P06241 | 1/20 | 0.65 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.65 |
| ▸ | GRB2 | P62993 | 1/20 | 0.65 |
| ▸ | HSD17B3 | P37058 | 12/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | GLA | P06280 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL4558147 | 0.99 | LCK (0.64) | LCKFYNAKR1B1GRB2HSD17B3 | |
| SCHEMBL2791708 | 0.85 | AKR1B1 (0.74) | LCKFYNAKR1B1GRB2HSD17B3 | |
| SCHEMBL16197641 | 0.84 | HSD17B3 (0.64) | LCKFYNAKR1B1GRB2HSD17B3 | |
| SCHEMBL10093731 | 0.83 | ALDH1A1 (0.71) | LCKFYNAKR1B1GRB2HSD17B3 | |
| SCHEMBL14618025 | 0.82 | ALDH1A1 (0.69) | LCKFYNAKR1B1GRB2HSD17B3 | |
| SCHEMBL23326972 | 0.80 | LCK (0.73) | LCKFYNAKR1B1GRB2HSD17B3 | |
| SCHEMBL263980 | 0.79 | AKR1B1 (1.00) | LCKFYNAKR1B1GRB2HSD17B3 | |
| SCHEMBL4215955 | 0.78 | HSD17B3 (0.75) | LCKFYNAKR1B1GRB2HSD17B3 | |
| SCHEMBL8396287 | 0.77 | HSD17B3 (0.69) | LCKFYNAKR1B1GRB2HSD17B3 | |
| SCHEMBL536846 | 0.76 | HSD17B3 (1.00) | LCKFYNAKR1B1GRB2HSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940506-B2 | High-sensitive fluorescent energy transfer assay using fluoresent amino acids and fluorescent proteins | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-01-27 | — | — | US | claimed |
| WO-2014046731-A1 | PREPARATION OF CYCLOTIDES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2014-03-27 | — | — | WO | claimed |
| US-20120329162-A1 | GENETICALLY ENCODED FLUORESCENT COUMARIN AMINO ACIDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-12-27 | — | — | US | claimed |
| US-8192952-B2 | Genetically encoded fluorescent coumarin amino acids | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-06-05 | — | — | US | claimed |
| US-7807411-B2 | Genetically encoded fluorescent coumarin amino acids | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-10-05 | — | — | US | claimed |
| US-20090298119-A1 | Genetically encoded coumarin amino acids | THE SCRIPPS RESEARCH INSTITUTE | 2009-12-03 | — | — | US | claimed |
| US-20080044886-A1 | Genetically encoded fluorescent coumarin amino acids | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-02-21 | — | — | US | claimed |
| EP-3355885-B1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS INC (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20250161468-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20240390507-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2024-11-28 | — | — | US | disclosed |
| US-20240165106-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2024-05-23 | — | — | US | disclosed |
| US-20240092846-A1 | ENGINEERED CYCLOTIDES WITH POTENT BROAD ANTIMICROBIAL ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-03-21 | — | — | US | disclosed |
| WO-2023156409-A1 | METHODS OF TREATING BLOOD DISORDERS WITH VWF-TARGETED MONOSPECIFIC ANTIBODIES | HEMAB APS (DK) | 2023-08-24 | — | — | WO | disclosed |
| US-20120077224-A1 | UNNATURAL AMINO ACID INCORPORATION IN EUKARYOTIC CELLS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2012-03-29 | — | — | US | disclosed |
| US-20110117556-A1 | HIGH-SENSITIVE FLUORESCENT ENERGY TRANSFER ASSAY USING FLUORESCENT AMINO ACIDS AND FLUORESENT PROTEINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-19 | — | — | US | disclosed |
| EP-2271662-A2 | HIGH-SENSITIVE FLUORESCENT ENERGY TRANSFER ASSAY USING FLUORESCENT AMINO ACIDS AND FLUORESENT PROTEINS | The Regents Of The University Of California (US) | 2011-01-12 | — | — | EP | disclosed |
| US-7807411-B2 | Genetically encoded fluorescent coumarin amino acids | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-10-05 | — | — | US | disclosed |
| US-20090298119-A1 | Genetically encoded coumarin amino acids | THE SCRIPPS RESEARCH INSTITUTE | 2009-12-03 | — | — | US | disclosed |
| WO-2009117726-A2 | HIGH-SENSITIVE FLUORESCENT ENERGY TRANSFER ASSAY USING FLUORESCENT AMINO ACIDS AND FLUORESENT PROTEINS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20080044886-A1 | Genetically encoded fluorescent coumarin amino acids | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165106-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRK1, OPRM1, CYP3A5 | LCK 3281/4885FYN 3199/4885AKR1B1 216/4885 |
| US-20110117556-A1 | HIGH-SENSITIVE FLUORESCENT ENERGY TRANSFER ASSAY USING FLUORESCENT AMINO ACIDS AND FLUORESENT PROTEINS | SLC7A1, SARS1, GFPT1 | LCK 1909/4885FYN 720/4885AKR1B1 4783/4885 |
| US-20250161468-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRL1 | LCK 3896/4885FYN 3515/4885AKR1B1 1085/4885 |
| US-20240390507-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRL1 | LCK 3896/4885FYN 3515/4885AKR1B1 1085/4885 |
| US-20080044886-A1 | Genetically encoded fluorescent coumarin amino acids | AARS1, GARS1, NSUN3 | LCK 3589/4885FYN 4378/4885AKR1B1 3145/4885 |
| US-20120329162-A1 | GENETICALLY ENCODED FLUORESCENT COUMARIN AMINO ACIDS | AARS1, GARS1, NSUN3 | LCK 3589/4885FYN 4378/4885AKR1B1 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.